Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameCloudbreak-B
Stock Code02592
Company Full NameCloudbreak Pharma Inc.
Industry醫療保健
Principal Activities公司是一間以創新驅動的臨床階段眼科生物科技公司,致力于開發新型及差異化療法,致力于內部發現、開發及商業化同類首創及同類最佳眼科療法,以滿足全球未滿足的醫療需要。
Listing Date2025-07-03
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)8921 Research Drive Irvine, CA 92618 United States
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.cloudbreakpharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 10.10 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 5,050
Par ValueTo be extracted
Offer Period2025-06-24 to 2025-06-27
Global Offering Shares60,582,000 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share29.2%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 611,878,200

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 5,050
2 lots 1,000 HK$ 10,100
3 lots 1,500 HK$ 15,150
4 lots 2,000 HK$ 20,200
5 lots 2,500 HK$ 25,250
6 lots 3,000 HK$ 30,300
7 lots 3,500 HK$ 35,350
8 lots 4,000 HK$ 40,400
9 lots 4,500 HK$ 45,450
10 lots 5,000 HK$ 50,500
12 lots 6,000 HK$ 60,600
14 lots 7,000 HK$ 70,700
16 lots 8,000 HK$ 80,800
18 lots 9,000 HK$ 90,900
20 lots 10,000 HK$ 101,000
30 lots 15,000 HK$ 151,500
40 lots 20,000 HK$ 202,000
50 lots 25,000 HK$ 252,500
60 lots 30,000 HK$ 303,000
70 lots 35,000 HK$ 353,500
80 lots 40,000 HK$ 404,000
90 lots 45,000 HK$ 454,500
100 lots 50,000 HK$ 505,000
120 lots 60,000 HK$ 606,000
140 lots 70,000 HK$ 707,000
160 lots 80,000 HK$ 808,000
180 lots 90,000 HK$ 909,000
200 lots 100,000 HK$ 1,010,000
400 lots 200,000 HK$ 2,020,000
600 lots 300,000 HK$ 3,030,000
800 lots 400,000 HK$ 4,040,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,000 lots 500,000 HK$ 5,050,000
1,200 lots 600,000 HK$ 6,060,000
1,400 lots 700,000 HK$ 7,070,000
1,600 lots 800,000 HK$ 8,080,000
1,800 lots 900,000 HK$ 9,090,000
2,000 lots 1,000,000 HK$ 10,100,000
4,000 lots 2,000,000 HK$ 20,200,000
6,058 lots 3,029,000 HK$ 30,592,900

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.42B
Est. Threshold HK$ 9.73B
Analysis Result HK market cap below threshold, need +583%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceUSD 34.86 million
Listing Expenses~HK$ 89,700,000
Listing Expenses / Funds Raised~14.7%
Total Pre-IPO Investmentapproximately USD 144.1 million
First Day CloseHK$ 6.2
First Day OpenHK$ 9.5
First Day Change-38.61%
First Day Volume43953200.0
First Day Turnover318762000.0
Use of Proceeds
1、約62.4%或325.9百萬港元將用于撥付核心產品CBT-001的持續臨床研發活動,以及注冊備案及獲批后研究所需資金; 2、約27.6%或144.1百萬港元將用于撥付持續臨床研發活動,包括研發人員及研發活動的成本及開支,以及核心產品CBT-009的注冊備案的所需資金; 3、約5.5%或28.7百萬港元將用于撥付生產設施及商業化活動所需資金; 4、約4.5%或23.5百萬港元將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
建银国际金融有限公司 CE AJO225 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (4)
建银国际金融有限公司 CE AJO225 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 招银国际融资有限公司 CE AVM940 Quam Securities Limited CE AAC577
Joint Bookrunners (19)
建银国际金融有限公司 CE AJO225 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 BOCI ASIA LIMITED CE AET863 交银国际证券有限公司 CE APJ121 中国银河国际证券(香港)有限公司 CE AXM459 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 民银证券有限公司 CE APU820 招银国际融资有限公司 CE AVM940 FIRST SHANGHAI SECURITIES LIMITED CE ABV488 Fosun International Securities Limited CE AAF432 Huafu International Securities Limited CE BQC241 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 Livermore Holdings Limited CE BJN764 PATRONS SECURITIES LIMITED CE BPQ161 Quam Securities Limited CE AAC577 Ruibang Securities Limited CE BIJ312 Soliton Securities Limited CE BMX492 SPDB International Capital Limited CE BFZ375 uSmart Securities Limited CE BJA907
Joint Lead Managers (19)
建银国际金融有限公司 CE AJO225 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 BOCI ASIA LIMITED CE AET863 交银国际证券有限公司 CE APJ121 中国银河国际证券(香港)有限公司 CE AXM459 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 民银证券有限公司 CE APU820 招银国际融资有限公司 CE AVM940 FIRST SHANGHAI SECURITIES LIMITED CE ABV488 Fosun International Securities Limited CE AAF432 Huafu International Securities Limited CE BQC241 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 Livermore Holdings Limited CE BJN764 PATRONS SECURITIES LIMITED CE BPQ161 Quam Securities Limited CE AAC577 Ruibang Securities Limited CE BIJ312 Soliton Securities Limited CE BMX492 SPDB International Capital Limited CE BFZ375 uSmart Securities Limited CE BJA907

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 The Reynold Lemkins Group (Asia) Limited 21,977,600 HKD — 3.59% — 6 months 2026-01-03
2 富策控股有限公司 156,994,400 HKD — 25.66% — 6 months 2026-01-03

Directors & Management

PositionChinese nameEnglish Name
ChairmanNI Jinsong—
Company Secretary歐子毅;馮雅芳—
No director data available.

Major Shareholders

Major Shareholders & HoldingsWater Lily Consultants Inc.(26.36%);澳美制藥廠有限公司(11.38%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The IPO attracted fierce retail interest, with an oversubscription ratio of 78.78 times pointing to intense demand for the stock. A hit rate of 25.52% means only about one in four applicants received allotments, typical of heavily subscribed deals. The final price of HKD 10.10 indicates pricing at the offer level, consistent with strong book-building momentum. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

At the A‑tail (400k HKD commitment), applicants expected just 1.0 lot, identical to the B‑head at 500k HKD, revealing a flat allocation curve where extra capital yields no incremental lots. This compression, driven by the 78.78 × oversubscription, creates inefficiency — the marginal 100k HKD delivers zero improvement in expected shares. For cost-sensitive participants, the A‑tail may offer better broker-fee efficiency than the B‑head, though actual costs vary by broker. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Mainland China investors dominated successful applications at 75.9%, highlighting strong cross-border enthusiasm for this IPO. The applicant pool skewed male (68%) and averaged 42.8 years old, suggesting experienced, mid‑career individuals with investable assets. No regional breakdown is available, but such offerings typically see heavy Guangdong concentration. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Cloudbreak-B (02592) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect